Consumer Alert: Abbott Laboratories Withdraws Its Obesity Drug Meridia

According to FDA, clinical trial testing of Meridia showed an increased risk of heart attacks and strokes in patients taking Meridia.

October 10, 2010

The drug maker Abbott Laboratories has agreed to take its weight loss and obesity drug Meridia (substance name sibutramine) off the market, the U.S. Food and Drug Administration ("FDA") announced Friday, October 8.  According to FDA, clinical trial testing of Meridia showed an increased risk of heart attacks and strokes in patients taking Meridia.[1] 

The new data showing that Meridia users suffer more heart attacks and strokes comes from the Sibutramine Cardiovascular Outcomes trial, known by its initials as the SCOUT trial.  The SCOUT data demonstrated a 16% increase in risk of major adverse cardiovascular events (defined as non-fatal heart attack, non-fatal stroke, resuscitation after cardiac arrest and cardiovascular death) in patients treated with Meridia compared to patients taking a placebo.[2]   At the end of the SCOUT trial, patients taking Meridia lost slightly more weight than patients taking placebo, but FDA has concluded that the risk for an adverse cardiovascular event from Meridia outweighed any benefit from that modest weight loss.[3]

In it's press release concerning the withdrawal, Abbott Laboratories instructs those taking Meridia to stop taking the drug and see their doctor for alternatives.[4]   

Robins, Kaplan, Miller & Ciresi L.L.P. is investigating potential claims on behalf of Meridia patients.  If you wish to speak to us about a potential claim or an injury caused by Meridia, please call Kathy Neuman, R.N., B.S.N. at 1-800-553-9910 or contact her via email at contact us.

[1] FDA New Release, "Abbott Laboratories agrees to withdraw its obesity drug Meridia (October 8, 2010) 
[2] FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine) [10-8-2010] 
[3] Id. 
[4] Abbott Press Release, "Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.   (October 8, 2010).

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.


Related Publications

January 18, 2022
Briefly: A User's Guide for Post-Trial Motions
Eric Magnuson and Caroline Moos - Minnesota Lawyer
December 21, 2021
Is This the End of Mandatory Arbitration?
David Rochelson - Antitrust, Vol. 36, No. 1, Fall 2021
December 2021
The Evolution and Practical Application of Genetic Testing
Teresa Fariss McClain - The Robins Kaplan Justice Report
Winter 2021
Avoiding Guilt by Association
Denise Rahne - The Robins Kaplan Spotlight, Vol. 6, No. 4
Winter 2021
Can You Keep a Secret? And Should You?
Anne Lockner - The Robins Kaplan Spotlight, Vol. 6, No. 4
Back to Top